Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Approved for marketing × Neoplasms × enzalutamide × Clear all

Status

Completed 7 Recruiting 3 Withdrawn 2 Active not recruiting 2 Approved for marketing 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Interventions

vorasidenib 1 tovorafenib 1 olaparib 1 glucarpidase 1 enzalutamide 1 adagrasib 1 Nivolumab 1 Carboxypeptidases 1 3-Iodobenzylguanidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01606982 2017-02-17

Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Astellas Pharma Inc

Approved for marketing

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡